FAB.LSE Fusion Antibodies PLC

Healthcare Life Sciences Tools & Services London Exchange
0.0600 GBX
Close of Oct 30, 2026
4.70 20.00
Market cap
GBX 7.51M
P/E
-
P/B
4.63x
ROE
-70.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Mar 2026.

Is FAB.LSE undervalued?

Graham number

The Graham number of Fusion Antibodies PLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Fusion Antibodies PLC fundamental analysis

No fundamental analysis for Fusion Antibodies PLC yet.

Fusion Antibodies PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Fusion Antibodies PLC

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing and engineering, antibody humanization and rational affinity maturation platform, recombinant protein expressions, and stable cel…

Full company profile